GenKyoTex S.A. Announces Successful Phase Ia Data with First in Class NOX Inhibitor GKT137831
6/22/2012 10:14:44 AM
GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the successful completion of a Phase Ia study with GKT137831, a first in class inhibitor targeting NOX1 and NOX4 enzymes. The results show that GKT137831 is safe and well tolerated following oral administration of single doses in 36 healthy subjects. Pharmacokinetic analysis demonstrates good dose proportional exposure to GKT137831 and confirms that once or twice a day oral dosing is a suitable regimen for further studies. A multiple dose Phase Ib study is currently underway.